Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ILK | Q13418 | 3/20 | 0.50 |
| ▸ | APEX1 | P27695 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15101513 | 0.87 | ADORA1 (0.55) | LMNAMAPTNPC1MEN1KMT2A | |
| SCHEMBL18295689 | 0.86 | MYC (0.57) | LMNAKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL18286100 | 0.85 | LMNA (0.46) | LMNAILKAPEX1KDM4EALDH1A1 | |
| SCHEMBL3752414 | 0.85 | APEX1 (0.66) | LMNAILKAPEX1KDM4EALDH1A1 | |
| SCHEMBL13833639 | 0.84 | LMNA (0.63) | LMNAAPEX1KDM4EALDH1A1MAPT | |
| SCHEMBL13833602 | 0.84 | LMNA (0.70) | LMNAAPEX1KDM4EALDH1A1MAPT | |
| SCHEMBL13833726 | 0.83 | LMNA (0.47) | LMNAAPEX1MAPTMEN1KMT2A | |
| SCHEMBL13737316 | 0.82 | APEX1 (0.67) | ILKAPEX1KDM4EALDH1A1MAPT | |
| SCHEMBL13833590 | 0.81 | APEX1 (0.77) | LMNAAPEX1KDM4EALDH1A1MAPT | |
| SCHEMBL13833669 | 0.81 | LMNA (0.66) | LMNAAPEX1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753418-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220048927-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | disclosed |
| US-11124527-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20180354972-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-12-13 | — | — | US | disclosed |
| WO-2016196910-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2012154888-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753418-B2 | Compounds for the modulation of Myc activity | MYC, MYCBP, MYCBP2 | LMNA 1426/4885ILK 2398/4885APEX1 962/4885 |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | HSPA5, PSMG3, VCP | LMNA 481/4885ILK 2762/4885APEX1 2669/4885 |
| US-20220048927-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | LMNA 1426/4885ILK 2398/4885APEX1 962/4885 |
| US-20180354972-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | LMNA 1426/4885ILK 2398/4885APEX1 962/4885 |
| US-11124527-B2 | Compounds for the modulation of Myc activity | MYC, MYCBP, MYCBP2 | LMNA 1426/4885ILK 2398/4885APEX1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.